Regulatory & Quality Assurance
United States of America
Kaye Spratt, PhD , Vice President, Regulatory & Quality Assurance, joined our company on November 1, 2015. Dr. Spratt has experience defining nonclinical development plans and strategies to US regulatory authorities. She has more than 20 years of scientific research, product development and translational expertise, with a focus on transitioning novel biologics through nonclinical and translation into Phase 1/2 human clinical trials. Dr. Spratt was Director of Preclinical and Quality Control at Sangamo BioSciences with increasing responsibilities from 1997 until 2015 and was responsible for leading a team of scientists developing novel cell and gene therapy products utilizing the Sangamo Zinc Finger Therapeutic strategy platform. She also has experience in the non-GLP and GLP toxicology and nonclinical safety evaluation of novel biologics and products for product development. Her primary biotech experience has focused on the development of non-viral and viral-mediated gene therapy approaches for monogenic and infectious diseases. Prior to joining Sangamo, Dr. Spratt was a Senior Scientist/Project Leader at Somatix Therapy Corporation. Dr. Spratt has over 40 publications in the Gene Therapy. Dr. Spratt earned her PhD in Microbiology with a focus in molecular biology in infectious diseases from Meharry Medical College. She also holds a B.S. in Biology from Langston University (Langston, OK).